197 related articles for article (PubMed ID: 10471530)
41. Optimizing dendritic cell-based immunotherapy in multiple myeloma.
Yi Q; Desikan R; Barlogie B; Munshi N
Br J Haematol; 2002 May; 117(2):297-305. PubMed ID: 11972511
[TBL] [Abstract][Full Text] [Related]
42. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells.
Li Y; Bendandi M; Deng Y; Dunbar C; Munshi N; Jagannath S; Kwak LW; Lyerly HK
Blood; 2000 Oct; 96(8):2828-33. PubMed ID: 11023518
[TBL] [Abstract][Full Text] [Related]
43. Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients.
Abdalla AO; Hansson L; Eriksson I; Näsman-Glaser B; Mellstedt H; Osterborg A
Eur J Haematol; 2007 Nov; 79(5):371-81. PubMed ID: 17916084
[TBL] [Abstract][Full Text] [Related]
44. Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study.
McCann KJ; Godeseth R; Chudley L; Mander A; Di Genova G; Lloyd-Evans P; Kerr JP; Malykh VB; Jenner MW; Orchard KH; Stevenson FK; Ottensmeier CH
Cancer Immunol Immunother; 2015 Aug; 64(8):1021-32. PubMed ID: 25982371
[TBL] [Abstract][Full Text] [Related]
45. Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing.
Frøyland M; Ruffini PA; Thompson KM; Gedde-Dahl T; Fredriksen AB; Bogen B
Eur J Haematol; 2011 May; 86(5):385-95. PubMed ID: 21332794
[TBL] [Abstract][Full Text] [Related]
46. Immunotherapy using dendritic cells against multiple myeloma: how to improve?
Nguyen-Pham TN; Lee YK; Kim HJ; Lee JJ
Clin Dev Immunol; 2012; 2012():397648. PubMed ID: 22481968
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.
Savelyeva N; King CA; Vitetta ES; Stevenson FK
Proc Natl Acad Sci U S A; 2005 Aug; 102(31):10987-92. PubMed ID: 16037207
[TBL] [Abstract][Full Text] [Related]
48. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma.
Hersey P; Menzies SW; Halliday GM; Nguyen T; Farrelly ML; DeSilva C; Lett M
Cancer Immunol Immunother; 2004 Feb; 53(2):125-34. PubMed ID: 14600790
[TBL] [Abstract][Full Text] [Related]
49. Successful cross-presentation of allogeneic myeloma cells by autologous alpha-type 1-polarized dendritic cells as an effective tumor antigen in myeloma patients with matched monoclonal immunoglobulins.
Yang DH; Kim MH; Lee YK; Hong CY; Lee HJ; Nguyen-Pham TN; Bae SY; Ahn JS; Kim YK; Chung IJ; Kim HJ; Kalinski P; Lee JJ
Ann Hematol; 2011 Dec; 90(12):1419-26. PubMed ID: 21465188
[TBL] [Abstract][Full Text] [Related]
50. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.
Rosenblatt J; Vasir B; Uhl L; Blotta S; Macnamara C; Somaiya P; Wu Z; Joyce R; Levine JD; Dombagoda D; Yuan YE; Francoeur K; Fitzgerald D; Richardson P; Weller E; Anderson K; Kufe D; Munshi N; Avigan D
Blood; 2011 Jan; 117(2):393-402. PubMed ID: 21030562
[TBL] [Abstract][Full Text] [Related]
51. Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells.
Betting DJ; Mu XY; Kafi K; McDonnel D; Rosas F; Gold DP; Timmerman JM
Vaccine; 2009 Jan; 27(2):250-9. PubMed ID: 19000731
[TBL] [Abstract][Full Text] [Related]
52. Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry.
Maecker HT; Auffermann-Gretzinger S; Nomura LE; Liso A; Czerwinski DK; Levy R
Clin Cancer Res; 2001 Mar; 7(3 Suppl):902s-908s. PubMed ID: 11300490
[TBL] [Abstract][Full Text] [Related]
53. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma.
Gadri Z; Kukulansky T; Bar-Or E; Haimovich J; Hollander N
J Immunother; 2009 May; 32(4):333-40. PubMed ID: 19342972
[TBL] [Abstract][Full Text] [Related]
54. Current vaccination strategies for the treatment of B-cell lymphoma and multiple myeloma.
Hollander N
Crit Rev Immunol; 2009; 29(5):399-418. PubMed ID: 20001888
[TBL] [Abstract][Full Text] [Related]
55. Idiotypic vaccination as therapy for multiple myeloma.
Kwak LW; Thielemans K; Massaia M
Semin Hematol; 1999 Jan; 36(1 Suppl 3):34-7. PubMed ID: 9989488
[TBL] [Abstract][Full Text] [Related]
56. Poor ex vivo induction of T-cell responses to idiotype or tumor cell lysate-pulsed autologous dendritic cells in advanced pre-treated multiple myeloma.
Garderet L; Mazurier C; Pellat-Deceunynck C; Karim A; Baudin B; Funck-Brentano C; Bouchet S; Geffroy A; Bataille R; Gorin NC; Lopez M
Leuk Lymphoma; 2006 Jul; 47(7):1340-7. PubMed ID: 16923566
[TBL] [Abstract][Full Text] [Related]
57. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients.
Bergenbrant S; Yi Q; Osterborg A; Björkholm M; Osby E; Mellstedt H; Lefvert AK; Holm G
Br J Haematol; 1996 Mar; 92(4):840-6. PubMed ID: 8616076
[TBL] [Abstract][Full Text] [Related]
58. Ex Vivo Induction of Multiple Myeloma-specific Immune Responses by Monocyte-derived Dendritic Cells Following Stimulation by Whole-tumor Antigen of Autologous Myeloma Cells.
Vasileiou S; Baltadakis I; Delimpasi S; Karatza MH; Liapis K; Garofalaki M; Tziotziou E; Poulopoulou Z; Karakasis D; Harhalakis N
J Immunother; 2017 Sep; 40(7):253-264. PubMed ID: 28763347
[TBL] [Abstract][Full Text] [Related]
59. Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.
Neeson P; Pan ZK; Paterson Y
Cancer Immunol Immunother; 2008 Apr; 57(4):493-505. PubMed ID: 17876582
[TBL] [Abstract][Full Text] [Related]
60. [In vitro anti-tumor effect of CTL induced by HSP70-Id complex-modified dendritic cells].
Wang ZH; Ye Q; Hu ZQ; Ye ZQ; Yu X; Shen GX
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):481-5. PubMed ID: 17147108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]